Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli-Institute for Cancer Research and Care (IRCCS), Rome, Italy.
Department of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Blood. 2022 Mar 10;139(10):1588-1592. doi: 10.1182/blood.2021014124.
In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to , Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.
在一篇全会论文中，Mittelman 及其同事评估了与健康匹配对照相比，mRNA 疫苗接种在血液恶性肿瘤患者中的 COVID-19 疾病发病率和结局方面的相对临床疗效。这项来自以色列的基于人群的研究将先前观察到的疫苗接种后血清学反应不佳与血液癌患者突破性感染、住院和死亡风险更高联系起来，尤其是那些正在接受积极抗肿瘤治疗的患者。在一篇相关的 Letter to 中，Pagano 等人采用多国调查方法提供了支持性数据，以捕捉血液恶性肿瘤患者 COVID-19 疫苗接种的结局。他们还强调了淋巴恶性肿瘤患者的风险更高。这些发现都呼吁为这一脆弱群体继续部署加强针计划和持续的公共卫生指导。
